ReWalk Robotics (NASDAQ:LFWD) Announces Earnings Results, Misses Estimates By $1.53 EPS

ReWalk Robotics (NASDAQ:LFWD) issued its quarterly earnings data on Friday. The company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.53), Zacks reports. ReWalk Robotics had a negative net margin of 77.21% and a negative return on equity of 43.02%. ReWalk Robotics updated its FY 2025 guidance to EPS.

ReWalk Robotics Trading Down 9.5 %

NASDAQ:LFWD traded down $0.15 during mid-day trading on Friday, hitting $1.43. The stock had a trading volume of 89,958 shares, compared to its average volume of 226,047. ReWalk Robotics has a 52 week low of $1.25 and a 52 week high of $6.00. The stock has a market capitalization of $15.20 million, a price-to-earnings ratio of -0.58 and a beta of 2.05. The company has a 50 day simple moving average of $1.77 and a 200-day simple moving average of $2.28.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on LFWD shares. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of ReWalk Robotics in a report on Thursday, February 20th. Lake Street Capital dropped their price target on ReWalk Robotics from $6.00 to $4.50 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Finally, Laidlaw initiated coverage on ReWalk Robotics in a research report on Monday, February 10th. They set a “buy” rating and a $10.00 price objective for the company.

Insiders Place Their Bets

In other ReWalk Robotics news, major shareholder Global Fund Lp Lind II sold 381,676 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $3.36, for a total transaction of $1,282,431.36. Following the completion of the transaction, the insider now owns 1,049,430 shares in the company, valued at approximately $3,526,084.80. The trade was a 26.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.50% of the stock is owned by insiders.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.